Patents by Inventor Stefan Dubel

Stefan Dubel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240059758
    Abstract: The present invention is related to antibodies and antigen-binding fragments of antibodies that specifically bind the SARS-CoV-2 glycoprotein S (spike) as well as diagnostic and therapeutic methods of using those antibodies.
    Type: Application
    Filed: May 19, 2021
    Publication date: February 22, 2024
    Inventors: André Frenzel, Philipp Kuhn, Jonas Kügler, Michael Hust, Stefan Dübel, Doris Meier, Federico Bertoglio, Maren Schubert, Stephan Steinke, Marlies Becker, Viola Fühner, Maximilian Ruschig, Philip Alexander Heine, Kai-Thomas Schneider, Rico Ballmann, Susanne Zock-Emmenthal, Kristian Daniel Ralph Roth, Nora Langreder
  • Publication number: 20210353733
    Abstract: The invention provides an antigenic peptide comprising an epitope for use in the prevention and/or treatment of an infection by C. difficile, e.g. for use as a vaccine in the prevention and/or treatment of an infection by C. difficile, and protective antibodies directed against the epitope.
    Type: Application
    Filed: September 19, 2018
    Publication date: November 18, 2021
    Inventors: Viola Fühner, Michael Hust, Stefan Dübel, Felix Löffler, Ralf Gerhard
  • Patent number: 11008402
    Abstract: The invention provides an antigen-binding protein that specifically binds to a conformational epitope formed by domain III & IV of human epidermal growth factor receptor 3 (HER3) and antigen-binding proteins which compete therewith for binding, as well as fusion protein or conjugate comprising these. The invention also provides nucleic acid molecule comprising a sequence encoding said antigen binding proteins, vectors comprising the nucleic acid, and cells and pharmaceuticals comprising the antigen binding protein, the fusion protein, the nucleic acid, or the vector. The invention also provides the antigen binding protein, the fusion protein or conjugate, the nucleic acid, the vector, the cell, or the pharmaceutical for use as a medicament.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: May 18, 2021
    Inventors: Roland Kontermann, Lisa Schmitt, Meike Hutt, Oliver Seifert, Monilola Olayioye, Michael Hust, Stefan Dübel, Jonas Zantow
  • Publication number: 20210030853
    Abstract: The present invention relates to combinations of tick-derived antigens for use as a tick vaccine.
    Type: Application
    Filed: April 17, 2019
    Publication date: February 4, 2021
    Applicant: Technische Universität Braunschweig
    Inventors: Michael HUST, Stefan DÜBEL
  • Patent number: 10730922
    Abstract: The present invention provides a composition comprising i) a polypeptide comprising calmodulin and two immunoglobulin superfamily domains, wherein said two immunoglobulin superfamily domains are linked via said calmodulin; ii) a calmodulin binding molecule; iii) ions binding to the Ca2+ binding site of calmodulin; wherein the binding of said calmodulin-binding molecule and of said ions to said Ca2+ binding site of calmodulin affects the binding of said polypeptide to an antigen to be bound by said polypeptide. The calmodulin may be a permutated calmodulin. A method for affecting the binding of a polypeptide for an antigen using said composition is also disclosed.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: August 4, 2020
    Assignee: Miltenyi Biotech B.V. & Co. KG
    Inventors: Stefan Dübel, Sarah-Jane Kellmann, Holger Thie
  • Publication number: 20190194350
    Abstract: The present invention provides an antigen-binding protein that specifically binds to a conformational epitope formed by domain III & IV of human epidermal growth factor receptor 3 (HER3) and antigen-binding proteins which compete therewith for binding, as well as fusion protein or conjugate comprising these. The present invention also provides nucleic acid molecule comprising a sequence encoding said antigen binding proteins, vectors comprising the nucleic acid, and cells and pharmaceuticals comprising the antigen binding protein, the fusion protein, the nucleic acid, or the vector. The present invention also provides the antigen binding protein, the fusion protein or conjugate, the nucleic acid, the vector, the cell, or the pharmaceutical for use as a medicament.
    Type: Application
    Filed: September 15, 2017
    Publication date: June 27, 2019
    Inventors: Roland KONTERMANN, Lisa SCHMITT, Meiko HUTT, Oliver SEIFERT, Monilola OLAYIOYE, Michael HUST, Stefan DÜBEL, Jonas ZANTOW
  • Publication number: 20180030104
    Abstract: The present invention provides a composition comprising i) a polypeptide comprising calmodulin and two immunoglobulin superfamily domains, wherein said two immunoglobulin superfamily domains are linked via said calmodulin; ii) a calmodulin binding molecule; iii) ions binding to the Ca2+ binding site of calmodulin; wherein the binding of said calmodulin-binding molecule and of said ions to said Ca2+ binding site of calmodulin affects the binding of said polypeptide to an antigen to be bound by said polypeptide. The calmodulin may be a permutated calmodulin. A method for affecting the binding of a polypeptide for an antigen using said composition is also disclosed.
    Type: Application
    Filed: July 14, 2017
    Publication date: February 1, 2018
    Inventors: Stefan DÜBEL, Sarah-Jane KELLMANN, Holger THIE
  • Patent number: 9752985
    Abstract: For the combinatorial synthesis of molecule libraries, substances are embedded in a matrix consisting of a first solvent thereby forming transport units in a solid state of aggregation at a temperature of less than 90° C. and wherein after application to a support, the physical environment of the transport units is modified by the application of a physical process such as a laser printer whereby the substances in the transport units are linked to the support.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: September 5, 2017
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS, EUROPÄISCHES LABORATORIUM FÜR MOLEKULARBIOLOGIE
    Inventors: Annemarie Poustka, Frank Breitling, Karl-Heinz Gross, Stefan Dübel, Rainer Saffrich
  • Patent number: 9546217
    Abstract: Antibodies having a high specificity and high affinity towards the human gene product MUC1, which in specific variants is associated with neoplastic cells, i.e. tumor tissue, to the use of the antibodies for medical purposes, i.e. for tumor treatment, and for analytical purposes, e.g. for tumor diagnosis. Compositions comprising the antibodies, e.g. for use in the analytical processes and analysis, to pharmaceutical compositions comprising the antibodies, and to use of the antibodies in the manufacture of pharmaceutical compositions for tumor treatment or for diagnostic purposes.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: January 17, 2017
    Assignee: MAB FACTORY GMBH
    Inventors: Christian Behrens, Holger Thie, Michael Hust, Lars Toleikis, Thomas Schirrmann, Stefan Dübel, Christophe De Romeuf
  • Patent number: 8344109
    Abstract: The subject of the present invention is an anti-ricin antibody and the use thereof for the treatment of an individual suffering from ricin poisoning.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: January 1, 2013
    Assignees: Etat Francais Represente par le Delegue General pour l'Armement, Technische Universitat Braunschweig-Institut fur Biochemie und Biotechnologie
    Inventors: Philippe Thullier, Michael Hust, Stefan Dubel
  • Publication number: 20110318757
    Abstract: Antibodies having a high specificity and high affinity towards the human gene product MUC1, which in specific variants is associated with neoplastic cells, i.e. tumor tissue, to the use of the antibodies for medical purposes, i.e. for tumor treatment, and for analytical purposes, e.g. for tumor diagnosis. Compositions comprising the antibodies, e.g. for use in the analytical processes and analyses, to pharmaceutical compositions comprising the antibodies, and to use of the antibodies in the manufacture of pharmaceutical compositions for tumor treatment or for diagnostic purposes.
    Type: Application
    Filed: July 17, 2009
    Publication date: December 29, 2011
    Inventors: Christian Behrens, Holger Thie, MIchael Hust, Lars Toleikis, Thomas Schirrmann, Stefan Dübel, Christophe De Romeouf
  • Publication number: 20110182878
    Abstract: The subject of the present invention is an anti-ricin antibody and the use thereof for the treatment of an individual suffering from ricin poisoning.
    Type: Application
    Filed: October 10, 2008
    Publication date: July 28, 2011
    Applicant: ETAT FRANCAIS represente par le Delegue General pour I'Armement
    Inventors: Philippe Thullier, Michael Hust, Stefan Dubel
  • Publication number: 20100015661
    Abstract: The present invention provides a novel antibody-RNase conjugate which is a single chain protein, providing both the specificity of its antibody portion and the RNase activity of its RNase portion, resulting in an antigen specific effectiveness against cells when applied in vivo or in vitro, wherein the RNase portion is effectively cytotoxic in at least a fraction of cells presenting the antigen, e.g. after internalization by endocytosis. In detail, the present invention provides scAb-RNase conjugate having the principal structure of scFvFc-RNase. This structure could also be shown to allow the effective production of antigen-specific and cytotoxic conjugate protein in cell culture, the conjugate having a high activity with respect to antigen specificity and cyto toxicity.
    Type: Application
    Filed: April 24, 2007
    Publication date: January 21, 2010
    Applicant: MAB-FACTORY GMBH
    Inventors: Stefan Dubel, Thomas Schirrmann, Thomas Jostok, Christian Menzel
  • Publication number: 20070274985
    Abstract: The present invention refers to synthetic antibody molecules which comprise domains from naturally occuring antibodies, e.g. domains derivable from IgG, preferably of human origin, in a novel arrangement. Single chain molecules are provided which are suitable for expression in micro-organisms in their active conformation, which single chain molecules generally comprise a VL domain, a CL domain, and a VH domain, a CH1 domain, linked by a linker arranged between VUCL and VH/CH1. Accordingly, these antibody molecules can be termed single chain Fabs (scFabs). These antibody molecules are single chain proteins, which can also be associated to dimers, including heteromeric antibodies, wherein at least two single chain antibody molecules are associated.
    Type: Application
    Filed: May 26, 2006
    Publication date: November 29, 2007
    Inventors: Stefan Dubel, Martina Inga Kirsch, Michael Hust, Thomas Jostock, Doris Meier
  • Publication number: 20050054000
    Abstract: The present invention relates to Fv constructs having an affinity that can be influenced for a substance to be linked, wherein the Fv constructs have peptides linked to the variable regions and containing binding sites for effector molecules. The invention also relates to a method of producing a single-chain Fv construct and the use of an Fv construct according to the invention for enriching and purifying substances.
    Type: Application
    Filed: August 10, 2001
    Publication date: March 10, 2005
    Inventor: Stefan Dubel
  • Publication number: 20040203085
    Abstract: The invention relates to a method for highly parallel production of complex molecule libraries on the surface of a substrate with the aid of regeneratable matrix dies. According to prior art, the production of molecule libraries on a support is expensive, and requires a lot of time and a large amount of apparatus. By using regeneratable matrix dies it is possible to simplify and accelerate the production of molecule libraries, especially DNA and protein libraries, in a significant manner. The matrix-10 die is made of an elastic material such as polydimethylsiloxane and includes locally-bound matrix molecules on the surface thereof, said molecules being used as a model for the synthesis of copy molecules. The copy molcules are transferred to the target surface by means of a contact printing method. The matrix molecules remain on the die for further synthesis and print cycles which can repeated several times. The inventive method is suitable for copying and reproducing differently produced molecule arrays.
    Type: Application
    Filed: April 29, 2004
    Publication date: October 14, 2004
    Inventors: Andre Bernard, Stefan Dubel
  • Patent number: 6730483
    Abstract: A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: May 4, 2004
    Assignee: Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts
    Inventors: Frank Breitling, Melvyn Little, Stefan Dübel, Michael Braunagel, Iris Klewinghaus
  • Publication number: 20020160463
    Abstract: A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.
    Type: Application
    Filed: April 8, 2002
    Publication date: October 31, 2002
    Applicant: Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts
    Inventors: Frank Breitling, Melvyn Little, Stefan Dubel, Michael Braunagel, Iris Klewinghaus
  • Patent number: 6387627
    Abstract: A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: May 14, 2002
    Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
    Inventors: Frank Breitling, Melvyn Little, Stefan Dübel, Michael Braunagel, Iris Klewinghaus
  • Publication number: 20020008871
    Abstract: According to the method for detecting optical properties, especially luminescence reactions and refraction behavior of molecules which are directly or indirectly bound on a support, electromagnetic waves, especially laser light, are radiated onto the support. The light that is emitted or refracted by the molecules is then detected by a detector. The detector and the support are moved in relation to each other during and after the radiation of the electromagnetic waves. The support used is especially a transparent support with integrated position markings which can be detected by a detector, especially an optoelectronic scanning system. At least one of the integrated position markings is selected while the support and the detector are being moved in relation to each other or thereafter so that the light that is detected by the detector can be associated with a location on the support.
    Type: Application
    Filed: June 13, 2001
    Publication date: January 24, 2002
    Inventors: Annemarie Poustka, Frank Breitling, Karl-Heinz Gross, Stefan Dubel, Rainer Saffrich